Samsung Biologics Presented New Tech in Boston
The company showcased its S-Tensify platform and streamlined manufacturing processes at BioProcess International 2026.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you believe advancements in drug manufacturing will lead to more affordable medications for you?
Samsung Biologics demonstrated new biopharmaceutical manufacturing capabilities at the BioProcess International 2026 conference in Boston. The presentation highlighted advances in process development timelines and cell-culture intensification platforms.
Why it matters
By reducing manufacturing timelines and increasing titer density, these technological refinements aim to accelerate the production of essential biopharmaceutical products. Such advancements help companies meet complex demand requirements more efficiently.
The S-Tensify cell-culture platform achieves up to a twofold improvement in titer. Samsung Biologics also reported that its molecule-specific process development now completes in 9.5 months, down from a previous 13-month benchmark.
The players
Samsung Biologics
This global contract development and manufacturing organization provides services for the production of biopharmaceutical products.
The details
Samsung Biologics operated a booth at the event to detail its integrated chemistry, manufacturing, and controls strategy for antibody production. The team focused on showcasing contract research and manufacturing capabilities to industry professionals.
Timeline
September 22-25, 2026: Samsung Biologics participated in BPI 2026.
Wednesday: A company team outlined their antibody process development strategy.
The Tech Race
Samsung Biologics has participated in BioProcess International for nine consecutive years, cementing its role in the global biopharmaceutical market. The move reflects an industry-wide push to replace legacy, slower production methods with high-density, integrated manufacturing workflows.
These improvements can lead to faster manufacturing cycles, potentially reducing the time required to bring new medical treatments to the market. For industry partners and developers, this means greater production efficiency and reduced development overhead.
The takeaway
Technological integration in manufacturing is becoming the standard for scaling complex biopharmaceutical production. Companies that adopt high-density cell-culture platforms effectively shorten the critical path from drug development to patient access.
Further reading
For more on industry developments, see our Biotech section.
Source note: This article includes information reported by The Korea Times.
Live Poll
Do you believe advancements in drug manufacturing will lead to more affordable medications for you?
